JNJ-63898081 is a bispecific antibody that targets CD3, which is expressed on T-cells and prostate- specific membrane antigen (PSMA) is highly expressed on prostate adenocarcinomas. JNJ-63898081 was created under a collaboration between Genmab and Janssen Biotech, Inc. using Genmab’s DuoBody® technology. 

Clinical studies
JNJ-63898081 is being investigated in a Phase I clinical study to treat advanced solid tumors.